| September 16, 2025 |
IR News
|
Presentation Materials Financial Results for the Fiscal Year Ended July 31 2025
|
| September 11, 2025 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors
|
| September 11, 2025 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
|
| September 10, 2025 |
Timely Disclosure Information
|
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors
|
| September 10, 2025 |
Timely Disclosure Information
|
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator
|
| September 10, 2025 |
Timely Disclosure Information
|
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
|
| September 10, 2025 |
Financial Results
|
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2025 [Japanese GAAP]
|
| July 22, 2025 |
Timely Disclosure Information
|
StemRIM Announces Progress of the Additional Phase 2 Clinical Trial on Redasemtide (HMGB1 Fragment Peptide) for Dystrophic Epidermolysis Bullosa
|
| June 16, 2025 |
Timely Disclosure Information
|
StemRIM Announces Publication of a Paper on Redasemtide (HMGB1 Fragment Peptide) for Liver Cirrhosis
|
| June 11, 2025 |
Timely Disclosure Information
|
Non-consolidated Financial Results for the Nine Months Ended April 30, 2025 [Japanese GAAP]
|
| May 20, 2025 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders (including Traumatic Cartilage Defect, Osteoarthritis, and Osteochondritis dissecans)
|
| April 9, 2025 |
Timely Disclosure Information
|
StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease)
|
| April 3, 2025 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic articular Cartilage Deficiency Syndrome, Osteoarthritis, and Osteochondritis dissecans
|
| April 2, 2025 |
Timely Disclosure Information
|
StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke
|
| March 17, 2025 |
Presentation Materials
|
Presentation Materials for Six Months Ended January 31 2025
|
